Previous 10 | Next 10 |
2023-11-14 06:30:08 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic For fu...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
2023-11-13 13:12:56 ET More on Immunic Immunic: Latest CALLIPER Data Reinforces Vidofludimus Calcium For Multiple Sclerosis Immunic jumps after the bell on positive interim data from phase 2 CALLIPER trial Seeking Alpha’s Quant Rating on Immunic Histor...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update PR Newswire – Webcast to be Held at 8:00 am ET on November 14, 2023 – NEW YORK , Nov. 7, 2023 /PRNewswire/ -- Immu...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts PR Newswire NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology co...
Immunic Inc. (IMUX) is expected to report $-0.55 for Q3 2023
Immunic to Participate in Scientific and Industry Conferences in November PR Newswire NEW YORK , Oct. 26, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...
--News Direct-- Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in form...
News, Short Squeeze, Breakout and More Instantly...
Immunic Inc. Company Name:
IMUX Stock Symbol:
NYSE Market:
--News Direct-- Immunic Inc CEO Daniel Vitt joined Steve Darling from Proactive to discuss the ongoing challenges and recent developments in treating multiple sclerosis (MS). This interview took place in conjunction with World MS Day, a day dedicated to raising global awareness about this...
Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK , May 28, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule thera...